[{"id":"page:/","kind":"page","name":"Start","aka":"","tldr":"Begin from a type of dementia, a care question, or the knowledge map.","tags":"page","route":"/","status":""},{"id":"page:/first-stages/","kind":"page","name":"First stages","aka":"","tldr":"Early signs and what to look for.","tags":"page","route":"/first-stages/","status":""},{"id":"page:/appointments/","kind":"page","name":"Appointments","aka":"","tldr":"First-visit checklist and care roadmap by stage.","tags":"page","route":"/appointments/","status":""},{"id":"page:/for-you/","kind":"page","name":"Care guide","aka":"","tldr":"Build a personal care guide with stage and topic filters.","tags":"page","route":"/for-you/","status":""},{"id":"page:/search/","kind":"page","name":"Search","aka":"","tldr":"Search dementia records and pages.","tags":"page","route":"/search/","status":""},{"id":"page:/compare/","kind":"page","name":"Compare","aka":"","tldr":"Compare dementia entities side by side.","tags":"page","route":"/compare/","status":""},{"id":"page:/diagnoses/","kind":"page","name":"Map","aka":"","tldr":"Diagnoses, treatments, trials, and the people and organisations behind them.","tags":"page","route":"/diagnoses/","status":""},{"id":"page:/treatments/","kind":"page","name":"Treatments","aka":"","tldr":"Approved and pipeline products, plus recruiting trials.","tags":"page","route":"/treatments/","status":""},{"id":"page:/explore/graph/","kind":"page","name":"Knowledge graph","aka":"","tldr":"Walk diagnosis to treatment to trial.","tags":"page","route":"/explore/graph/","status":""},{"id":"page:/explore/who/","kind":"page","name":"Who","aka":"","tldr":"Companies, institutions, and cited public figures.","tags":"page","route":"/explore/who/","status":""},{"id":"page:/explore/trials/","kind":"page","name":"Trials on the map","aka":"","tldr":"Plain-language trial records, including failures.","tags":"page","route":"/explore/trials/","status":""},{"id":"page:/guidelines/","kind":"page","name":"Guidelines","aka":"","tldr":"NICE NG97 and related regulator pages this atlas cites.","tags":"page","route":"/guidelines/","status":""},{"id":"page:/research/","kind":"page","name":"Glossary","aka":"","tldr":"Terms used in medicine and diagnosis.","tags":"page","route":"/research/","status":""},{"id":"page:/about/","kind":"page","name":"Trust","aka":"","tldr":"What this atlas is, how it is built, and how to get help.","tags":"page","route":"/about/","status":""},{"id":"page:/resources/","kind":"page","name":"Resources","aka":"","tldr":"Helplines and urgent support.","tags":"page","route":"/resources/","status":""},{"id":"page:/privacy/","kind":"page","name":"Privacy","aka":"","tldr":"What this site stores.","tags":"page","route":"/privacy/","status":""},{"id":"page:/terms-of-use/","kind":"page","name":"Terms of use","aka":"","tldr":"Not medical advice.","tags":"page","route":"/terms-of-use/","status":""},{"id":"page:/changelog/","kind":"page","name":"Changelog","aka":"","tldr":"What changed.","tags":"page","route":"/changelog/","status":""},{"id":"page:/corrections/","kind":"page","name":"Corrections","aka":"","tldr":"How to report an error.","tags":"page","route":"/corrections/","status":""},{"id":"dementia","kind":"cancer","name":"Dementia (umbrella)","aka":"","tldr":"Dementia is an umbrella term for changes that affect thinking, memory, communication, and everyday tasks. It is not a normal part of ageing.","tags":"dementia-atlas","route":"/diagnoses/dementia/"},{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","aka":"","tldr":"Alzheimer’s disease is a brain disease that commonly causes dementia. Early-stage anti-amyloid medicines exist for a carefully selected group, and several older medicines can support cognitive symptoms.","tags":"dementia-atlas","route":"/diagnoses/alzheimers-disease/"},{"id":"dementia-with-lewy-bodies","kind":"cancer","name":"Dementia with Lewy bodies","aka":"","tldr":"Dementia with Lewy bodies often mixes thinking changes with fluctuating alertness, visual hallucinations, sleep-acting-out, and movement symptoms. Antipsychotics can cause severe sensitivity reactions.","tags":"dementia-atlas","route":"/diagnoses/dementia-with-lewy-bodies/"},{"id":"parkinsons-disease-dementia","kind":"cancer","name":"Parkinson’s disease dementia","aka":"","tldr":"Parkinson’s disease dementia is dementia that appears in the setting of established Parkinson’s disease. Rivastigmine has an FDA indication for this use and is a symptom treatment, not disease-modifying.","tags":"dementia-atlas","route":"/diagnoses/parkinsons-disease-dementia/"},{"id":"vascular-dementia","kind":"cancer","name":"Vascular dementia","aka":"","tldr":"Vascular dementia follows stroke or other blood-vessel injury in the brain. There is no FDA-approved medicine specifically for its cognitive symptoms. Vascular risk care still matters.","tags":"dementia-atlas","route":"/diagnoses/vascular-dementia/"},{"id":"frontotemporal-dementia","kind":"cancer","name":"Frontotemporal dementia","aka":"","tldr":"Frontotemporal dementia often changes behaviour, personality, or language earlier than memory. There is no FDA-approved medicine specifically for its cognitive symptoms.","tags":"dementia-atlas","route":"/diagnoses/frontotemporal-dementia/"},{"id":"mixed-dementia","kind":"cancer","name":"Mixed dementia","aka":"","tldr":"Mixed dementia means more than one brain disease is contributing, often Alzheimer’s pathology plus vascular injury. Trial results from pure Alzheimer’s cohorts may not apply unchanged.","tags":"dementia-atlas","route":"/diagnoses/mixed-dementia/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","aka":"","tldr":"Mild cognitive impairment means thinking changes are noticeable on testing, but everyday independence is largely preserved. Some people later develop dementia. Others stay stable or improve.","tags":"dementia-atlas","route":"/diagnoses/mild-cognitive-impairment/"},{"id":"da-front-imaging","kind":"section","name":"Imaging","aka":"","tldr":"Scans that show brain structure and, in selected people, amyloid or other biology.","tags":"dementia-atlas","route":"/fronts/da-front-imaging/"},{"id":"da-front-fluid-biomarkers","kind":"section","name":"Fluid biomarkers","aka":"","tldr":"Spinal-fluid and blood tests that can support an Alzheimer’s biology question.","tags":"dementia-atlas","route":"/fronts/da-front-fluid-biomarkers/"},{"id":"da-front-genetics","kind":"section","name":"Genetics","aka":"","tldr":"Genes can change risk and, rarely, cause familial disease. ApoE ε4 also changes antibody-safety counselling.","tags":"dementia-atlas","route":"/fronts/da-front-genetics/"},{"id":"da-front-symptomatic-care","kind":"section","name":"Symptomatic care","aka":"","tldr":"Medicines and non-drug support aimed at symptoms, not at reversing the disease.","tags":"dementia-atlas","route":"/fronts/da-front-symptomatic-care/"},{"id":"da-front-anti-amyloid","kind":"section","name":"Anti-amyloid treatment","aka":"","tldr":"Antibodies that lower amyloid plaques in early symptomatic Alzheimer’s disease, with ARIA monitoring.","tags":"dementia-atlas","route":"/fronts/da-front-anti-amyloid/"},{"id":"da-front-anti-tau","kind":"section","name":"Anti-tau research","aka":"","tldr":"Tau is the tangle protein. Treatments that lower or block tau remain investigational.","tags":"dementia-atlas","route":"/fronts/da-front-anti-tau/"},{"id":"da-front-neuroinflammation","kind":"section","name":"Neuroinflammation","aka":"","tldr":"Immune activity in the brain is a research front, not a licensed dementia cure.","tags":"dementia-atlas","route":"/fronts/da-front-neuroinflammation/"},{"id":"da-front-lifestyle-risk","kind":"section","name":"Lifestyle and risk","aka":"","tldr":"Hearing, blood pressure, smoking, sleep, and movement are part of brain-health care. They are not a substitute for diagnosis.","tags":"dementia-atlas","route":"/fronts/da-front-lifestyle-risk/"},{"id":"da-front-digital-cognition","kind":"section","name":"Digital cognition","aka":"","tldr":"Apps and remote tests can track change. They do not diagnose dementia on their own.","tags":"dementia-atlas","route":"/fronts/da-front-digital-cognition/"},{"id":"da-front-ai","kind":"section","name":"AI in dementia care","aka":"","tldr":"Software can help read scans or organise notes. It is not a clinician and it is not a diagnosis.","tags":"dementia-atlas","route":"/fronts/da-front-ai/"},{"id":"da-front-care-delivery","kind":"section","name":"Care delivery","aka":"","tldr":"Who coordinates care, how families get respite, and how clinics monitor antibodies are delivery problems, not only science problems.","tags":"dementia-atlas","route":"/fronts/da-front-care-delivery/"},{"id":"da-tech-mri","kind":"technology","name":"Brain MRI","aka":"","tldr":"MRI looks at brain structure and is used to watch for swelling or bleeding when someone receives an amyloid antibody.","tags":"dementia-atlas","route":"/technologies/da-tech-mri/","cancers":"alzheimers-disease vascular-dementia"},{"id":"da-tech-amyloid-pet","kind":"technology","name":"Amyloid PET","aka":"","tldr":"Amyloid PET is a scan that can show whether amyloid plaques are present. It is used when the result will change care, not as a screening test.","tags":"dementia-atlas","route":"/technologies/da-tech-amyloid-pet/","cancers":"alzheimers-disease"},{"id":"da-tech-csf-biomarkers","kind":"technology","name":"CSF amyloid and tau","aka":"","tldr":"A spinal-fluid test can support an Alzheimer’s biology question in specialist clinics.","tags":"dementia-atlas","route":"/technologies/da-tech-csf-biomarkers/","cancers":"alzheimers-disease"},{"id":"da-tech-blood-biomarkers","kind":"technology","name":"Blood Alzheimer biomarkers","aka":"","tldr":"Blood tests may help decide who needs a scan or spinal-fluid test. They are not a home diagnosis.","tags":"dementia-atlas","route":"/technologies/da-tech-blood-biomarkers/","status":"emerging","cancers":"alzheimers-disease mild-cognitive-impairment"},{"id":"da-tech-apoe-testing","kind":"technology","name":"ApoE testing","aka":"","tldr":"ApoE ε4 is a risk variant used in antibody-safety counselling. It does not diagnose Alzheimer’s disease.","tags":"dementia-atlas","route":"/technologies/da-tech-apoe-testing/","cancers":"alzheimers-disease"},{"id":"da-tech-cholinesterase-inhibitors","kind":"technology","name":"Cholinesterase inhibitors","aka":"","tldr":"These older medicines can support cognitive symptoms for some people. They are not disease-modifying.","tags":"dementia-atlas","route":"/technologies/da-tech-cholinesterase-inhibitors/"},{"id":"da-tech-anti-amyloid-mab","kind":"technology","name":"Anti-amyloid antibodies","aka":"","tldr":"Infused antibodies can lower amyloid in early Alzheimer’s disease. They need monitoring for brain swelling or bleeding on MRI.","tags":"dementia-atlas","route":"/technologies/da-tech-anti-amyloid-mab/"},{"id":"da-tech-tau-therapeutics","kind":"technology","name":"Tau-directed therapeutics","aka":"","tldr":"Tau-directed treatments are in trials. None is an approved dementia medicine on this atlas.","tags":"dementia-atlas","route":"/technologies/da-tech-tau-therapeutics/","status":"emerging"},{"id":"da-tech-digital-cognition","kind":"technology","name":"Digital cognitive testing","aka":"","tldr":"Digital tests can track change. They do not replace a clinical assessment.","tags":"dementia-atlas","route":"/technologies/da-tech-digital-cognition/","status":"emerging"},{"id":"da-tech-care-navigation","kind":"technology","name":"Dementia care navigation","aka":"","tldr":"A care navigator helps the household use the system. It is support, not a treatment for the brain disease.","tags":"dementia-atlas","route":"/technologies/da-tech-care-navigation/"},{"id":"da-target-amyloid-beta","kind":"target","name":"Amyloid-beta","aka":"","tldr":"Amyloid-beta is the protein fragment that forms plaques in Alzheimer’s disease. Clearing it is the idea behind several antibodies.","tags":"dementia-atlas","route":"/targets/da-target-amyloid-beta/","cancers":"alzheimers-disease"},{"id":"da-target-tau","kind":"target","name":"Tau","aka":"","tldr":"Tau is the tangle protein. Its spread tracks symptoms more closely than plaques in many studies.","tags":"dementia-atlas","route":"/targets/da-target-tau/","cancers":"alzheimers-disease frontotemporal-dementia"},{"id":"da-target-ache","kind":"target","name":"Acetylcholinesterase","aka":"","tldr":"Blocking this enzyme is how donepezil, rivastigmine, and galantamine try to support signalling.","tags":"dementia-atlas","route":"/targets/da-target-ache/"},{"id":"da-target-alpha-synuclein","kind":"target","name":"Alpha-synuclein","aka":"","tldr":"Alpha-synuclein is the protein in Lewy bodies. There is no approved treatment that clears it in dementia.","tags":"dementia-atlas","route":"/targets/da-target-alpha-synuclein/","cancers":"dementia-with-lewy-bodies parkinsons-disease-dementia"},{"id":"da-target-tdp43","kind":"target","name":"TDP-43","aka":"","tldr":"TDP-43 is a protein involved in some frontotemporal and related diseases. It is a research target, not a licensed treatment.","tags":"dementia-atlas","route":"/targets/da-target-tdp43/","cancers":"frontotemporal-dementia"},{"id":"da-lecanemab","kind":"drug","name":"Lecanemab","aka":"","tldr":"Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.","tags":"dementia-atlas","route":"/drugs/da-lecanemab/","status":"approved","cancers":"alzheimers-disease mild-cognitive-impairment"},{"id":"da-donanemab","kind":"drug","name":"Donanemab","aka":"","tldr":"Donanemab is a monthly infused antibody for early Alzheimer’s disease after amyloid confirmation, with the same ARIA monitoring theme as other amyloid antibodies.","tags":"dementia-atlas","route":"/drugs/da-donanemab/","status":"approved","cancers":"alzheimers-disease mild-cognitive-impairment"},{"id":"da-donepezil","kind":"drug","name":"Donepezil","aka":"","tldr":"Donepezil is a tablet used for cognitive symptoms in Alzheimer’s disease. It may help some people a little. It does not slow the disease itself.","tags":"dementia-atlas","route":"/drugs/da-donepezil/","status":"approved","cancers":"alzheimers-disease"},{"id":"da-rivastigmine","kind":"drug","name":"Rivastigmine","aka":"","tldr":"Rivastigmine is used for Alzheimer’s dementia and has a US indication for dementia associated with Parkinson’s disease. It is a symptom treatment.","tags":"dementia-atlas","route":"/drugs/da-rivastigmine/","status":"approved","cancers":"alzheimers-disease parkinsons-disease-dementia dementia-with-lewy-bodies"},{"id":"da-galantamine","kind":"drug","name":"Galantamine","aka":"","tldr":"Galantamine is a tablet for mild-to-moderate dementia of the Alzheimer’s type. It is not approved for vascular, frontotemporal, or Lewy body dementia.","tags":"dementia-atlas","route":"/drugs/da-galantamine/","status":"approved","cancers":"alzheimers-disease"},{"id":"da-memantine","kind":"drug","name":"Memantine","aka":"","tldr":"Memantine is a tablet used in moderate-to-severe dementia of the Alzheimer’s type. It is a symptom treatment, sometimes combined with a cholinesterase inhibitor.","tags":"dementia-atlas","route":"/drugs/da-memantine/","status":"approved","cancers":"alzheimers-disease"},{"id":"da-brexpiprazole","kind":"drug","name":"Brexpiprazole","aka":"","tldr":"Brexpiprazole has a US indication for agitation in Alzheimer’s dementia after other causes are considered. Antipsychotics increase mortality in elderly people with dementia-related psychosis.","tags":"dementia-atlas","route":"/drugs/da-brexpiprazole/","status":"approved","cancers":"alzheimers-disease"},{"id":"da-aducanumab","kind":"drug","name":"Aducanumab","aka":"","tldr":"Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.","tags":"dementia-atlas","route":"/drugs/da-aducanumab/","status":"withdrawn","cancers":"alzheimers-disease"},{"id":"da-remternetug","kind":"drug","name":"Remternetug","aka":"","tldr":"Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.","tags":"dementia-atlas","route":"/drugs/da-remternetug/","status":"phase-3","cancers":"alzheimers-disease"},{"id":"da-trial-clarity-ad","kind":"trial","name":"CLARITY AD","aka":"","tldr":"CLARITY AD tested lecanemab in early Alzheimer’s disease. It is the main efficacy trial behind the US traditional approval.","tags":"dementia-atlas","route":"/trials/da-trial-clarity-ad/","status":"completed","cancers":"alzheimers-disease"},{"id":"da-trial-trailblazer-alz2","kind":"trial","name":"TRAILBLAZER-ALZ 2","aka":"","tldr":"TRAILBLAZER-ALZ 2 tested donanemab in early Alzheimer’s disease and is the main efficacy trial behind the US approval.","tags":"dementia-atlas","route":"/trials/da-trial-trailblazer-alz2/","status":"completed","cancers":"alzheimers-disease"},{"id":"da-trial-engage","kind":"trial","name":"ENGAGE","aka":"","tldr":"ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug.","tags":"dementia-atlas","route":"/trials/da-trial-engage/","status":"negative","cancers":"alzheimers-disease"},{"id":"da-trial-expedition3","kind":"trial","name":"EXPEDITION 3","aka":"","tldr":"EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result.","tags":"dementia-atlas","route":"/trials/da-trial-expedition3/","status":"negative","cancers":"alzheimers-disease"},{"id":"da-eisai","kind":"company","name":"Eisai","aka":"","tldr":"Eisai is a medicines company that co-developed lecanemab.","tags":"dementia-atlas","route":"/companies/da-eisai/"},{"id":"da-biogen","kind":"company","name":"Biogen","aka":"","tldr":"Biogen partnered on lecanemab and previously marketed aducanumab.","tags":"dementia-atlas","route":"/companies/da-biogen/"},{"id":"da-lilly","kind":"company","name":"Eli Lilly","aka":"","tldr":"Lilly developed donanemab and is running further amyloid-antibody studies.","tags":"dementia-atlas","route":"/companies/da-lilly/"},{"id":"da-nia","kind":"institution","name":"National Institute on Aging","aka":"","tldr":"The US National Institute on Aging publishes public pages on Alzheimer’s disease, MCI, and caregiving.","tags":"dementia-atlas","route":"/institutions/da-nia/"},{"id":"da-alz-assoc","kind":"institution","name":"Alzheimer's Association","aka":"","tldr":"A US nonprofit that publishes public pages on dementia types, symptoms, and medicines. It is not a clinic.","tags":"dementia-atlas","route":"/institutions/da-alz-assoc/"},{"id":"da-nice","kind":"institution","name":"NICE","aka":"","tldr":"NICE publishes NG97 on dementia assessment, management, and support for people and carers in England.","tags":"dementia-atlas","route":"/institutions/da-nice/"},{"id":"da-ucl-dementia","kind":"institution","name":"UCL","aka":"","tldr":"University College London is a public research university. This node marks a UK academic neighbour, not a ranked best-centre list.","tags":"dementia-atlas","route":"/institutions/da-ucl-dementia/"},{"id":"alois-alzheimer","kind":"person","name":"Alois Alzheimer","aka":"","tldr":"Alois Alzheimer was a physician whose 1906 case description is why Alzheimer’s disease has that name. This is a historical biography, not a doctor to contact.","tags":"dementia-atlas","route":"/people/alois-alzheimer/","cancers":"alzheimers-disease"},{"id":"da-pair-lecanemab-mri","kind":"pairing","name":"Lecanemab with MRI monitoring","aka":"","tldr":"Amyloid antibodies are used with scheduled MRI checks for ARIA, not as a standalone infusion without imaging follow-up.","tags":"dementia-atlas","route":"/pairings/da-pair-lecanemab-mri/","cancers":"alzheimers-disease"},{"id":"da-journal-nejm","kind":"journal","name":"New England Journal of Medicine","aka":"","tldr":"A general medical journal. CLARITY AD was published here. Listing the journal is not an endorsement of every paper it carries.","tags":"dementia-atlas","route":"/journals/da-journal-nejm/"},{"id":"da-paper-clarity-ad","kind":"paper","name":"Lecanemab in Early Alzheimer’s Disease (CLARITY AD)","aka":"","tldr":"The published CLARITY AD paper reports the phase 3 lecanemab trial in early Alzheimer’s disease. Read the paper and the FDA communication together.","tags":"dementia-atlas","route":"/key-papers/da-paper-clarity-ad/","cancers":"alzheimers-disease"},{"id":"da-pathway-amyloid-tau","kind":"pathway","name":"Amyloid and tau cascade (simplified)","aka":"","tldr":"A simplified drawing of how amyloid and tau are often described in Alzheimer’s disease. Real brains are messier, and mixed pathology is common.","tags":"dementia-atlas","route":"/pathways/da-pathway-amyloid-tau/","cancers":"alzheimers-disease"},{"id":"da-term-aria","kind":"term","name":"ARIA","aka":"amyloid-related imaging abnormalities","tldr":"ARIA is swelling or bleeding seen on MRI in people receiving amyloid antibodies. It can be silent or, less often, symptomatic.","tags":"dementia-atlas","route":"/terms/da-term-aria/"},{"id":"da-term-amyloid-pet","kind":"term","name":"Amyloid PET","aka":"","tldr":"A PET scan that can show amyloid plaques. It answers a biology question, not 'how severe is the dementia'.","tags":"dementia-atlas","route":"/terms/da-term-amyloid-pet/"},{"id":"da-term-mci","kind":"term","name":"Mild cognitive impairment","aka":"MCI","tldr":"Thinking changes that are noticeable but do not, by themselves, take away everyday independence.","tags":"dementia-atlas","route":"/terms/da-term-mci/","cancers":"mild-cognitive-impairment"},{"id":"da-term-mixed-dementia","kind":"term","name":"Mixed dementia","aka":"","tldr":"More than one brain disease is contributing, often Alzheimer’s pathology plus vascular injury.","tags":"dementia-atlas","route":"/terms/da-term-mixed-dementia/","cancers":"mixed-dementia"},{"id":"da-bn-late-diagnosis","kind":"bottleneck","name":"Late and uneven diagnosis","aka":"","tldr":"Many people receive a dementia diagnosis late, or never receive a subtype. That blocks both care planning and trial entry.","tags":"dementia-atlas","route":"/bottlenecks/da-bn-late-diagnosis/","cancers":"dementia alzheimers-disease"},{"id":"da-bn-trial-exclusion","kind":"bottleneck","name":"Trial populations that skip mixed disease","aka":"","tldr":"Antibody trials largely enrolled people with biomarker-supported Alzheimer’s disease and excluded much mixed, vascular, and diverse disease.","tags":"dementia-atlas","route":"/bottlenecks/da-bn-trial-exclusion/","cancers":"alzheimers-disease mixed-dementia"},{"id":"da-bn-caregiver-load","kind":"bottleneck","name":"Unpaid care as the hidden delivery system","aka":"","tldr":"Most day-to-day dementia care is unpaid. Medicines and scans fail in practice if one person is carrying every task alone.","tags":"dementia-atlas","route":"/bottlenecks/da-bn-caregiver-load/"},{"id":"da-bn-subtype-misclassification","kind":"bottleneck","name":"Wrong-subtype treatment","aka":"","tldr":"Lewy body, vascular, and frontotemporal dementia are still treated as if they were typical Alzheimer’s disease, which can add harm.","tags":"dementia-atlas","route":"/bottlenecks/da-bn-subtype-misclassification/","cancers":"dementia-with-lewy-bodies frontotemporal-dementia vascular-dementia"},{"id":"da-idea-blood-first-triage","kind":"idea","name":"Blood test before PET or lumbar puncture","aka":"","tldr":"Use a blood test to decide who still needs a scan or spinal-fluid test, instead of sending everyone to PET.","tags":"dementia-atlas","route":"/ideas/da-idea-blood-first-triage/","cancers":"alzheimers-disease mild-cognitive-impairment"},{"id":"da-idea-inclusive-anti-amyloid-trials","kind":"idea","name":"Antibody trials that enrol mixed and comorbid disease","aka":"","tldr":"Test amyloid antibodies in the mixed, comorbid people clinics actually see, instead of only in tidy trial cohorts.","tags":"dementia-atlas","route":"/ideas/da-idea-inclusive-anti-amyloid-trials/","cancers":"alzheimers-disease mixed-dementia"},{"id":"da-idea-carer-outcome-primary","kind":"idea","name":"Make carer outcomes a primary trial endpoint","aka":"","tldr":"Judge dementia treatments by whether households cope better, not only by a clinic memory score.","tags":"dementia-atlas","route":"/ideas/da-idea-carer-outcome-primary/"},{"id":"da-roadmap-anti-amyloid","kind":"roadmap","name":"Anti-amyloid medicines","aka":"","tldr":"From failed or withdrawn antibodies to two US-approved early-stage products, with access and ARIA still open.","tags":"dementia-atlas","route":"/roadmaps/da-roadmap-anti-amyloid/","cancers":"alzheimers-disease"},{"id":"da-collection-clinicaltrials","kind":"collection","name":"ClinicalTrials.gov","aka":"","tldr":"ClinicalTrials.gov is the public US trial registry. A listing is not a recommendation to join a study.","tags":"dementia-atlas","route":"/collections/da-collection-clinicaltrials/"}]